Abstract:Background: We have previously shown that 15 urinary biomarkers (of 129 tested by Luminex), discriminate between active Lupus Nephritis (ALN) and non-LN patients. The aim of this study was to evaluate the ability of these 15 previously-identified urinary biomarkers to predict treatment responses to conventional therapy, and for the most predictive of these biomarkers to validate their utility to identify ALN patients in an independent prospectively-acquired lupus cohort. Methods: Our study had a 3-stage approach. In stage 1, we used Luminex to examine whether our previously identified urinary biomarkers at the time of the renal flare ( ± 3 months) or 12 ± 3 months after treatment of biopsy-proven ALN could predict treatment responses. In stage 2, a larger prospectively-acquired cross-sectional cohort was used to further validate the utility of the most predictive urinary biomarkers (identified in stage 1) to detect ALN patients. In this 2nd stage, cut-offs with the best operating characteristics to detect ALN patients were produced for each biomarker and different combinations and/or numbers of elevated biomarkers needed to accurately identify ALN patients were analyzed. In stage 3, we aimed to further corroborate the sensitivity of the cut-offs created in stage 2 to detect ALN patients in a biopsy-proven ALN cohort who had a urine sample collection within 3 months of their biopsy. Results: Twenty-one patients were included in stage 1. Twelve (57.1%), 4 (19.1%), and 5 (23.8%) patients had a complete (CR), partial (PR) and no (NR) remission at 24 ± 3 months, respectively. The percentage decrease following 12 ± 3 months of treatment for Adiponectin, MCP-1, sVCAM-1, PF4, IL-15 and vWF was significantly higher in patients with CR in comparison to those with PR/NR. In stage 2, a total of 247 SLE patients were included, of which 24 (9.7%) had ALN, 79 (31.9%) had LN in remission (RLN) and 144 (58.3%) were non-LN (NLN) patients. Based on the combinations of biomarkers with the best operating characteristics we propose "rule out" and "rule in" ALN criteria. In stage 3, 53 biopsy-proven ALN patients were included, 35 with proliferative LN and 18 with non-proliferative ALN, demonstrating that our "rule in ALN" criteria operate better in detecting active proliferative than non-proliferative classes. Conclusions: Our results provide further evidence to support the role of Adiponectin, MCP-1, sVCAM-1 and PF4 in the detection of proliferative ALN cases. We further show the clinical utility of measuring multiple rather than a single biomarker and we propose novel "rule in" and "rule out" criteria for the detection of proliferative ALN with excellent operating characteristics.

Urinary biomarkers associated with pathogenic pathways reflecting histological findings in lupus nephritis

Urinary Biomarkers Associated With Pathogenic Pathways Reflecting Histologic Findings in Lupus Nephritis

THU0247 LRRN4: A NOVEL PROGNOSTIC BIOMARKER OF RENAL OUTCOME IN LUPUS NEPHRITIS PATIENTS

Early-stage predictors for treatment responses in patients with active lupus nephritis.

Tubular biomarkers and histology in lupus nephritis

Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis

The novel involvement of podocyte autophagic activity in the pathogenesis of lupus nephritis.

Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts

Investigating the value of urinary biomarkers in relation to lupus nephritis histopathology: present insights and future prospects

Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis

Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis

Composite Urinary Biomarkers to Predict Pathological Tubulointerstitial Lesions in Lupus Nephritis.

Urinary biomarkers associated with podocyte injury in lupus nephritis

Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis

Increased Urinary Interleukin 22 Binding Protein Levels Correlate with Lupus Nephritis Activity

Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology

Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities

Urinary galectin-3 binding protein (G3BP) as a biomarker for disease activity and renal pathology characteristics in lupus nephritis

Noninvasive biomarkers for lupus nephritis

IGFBP2 Function As a Novel Biomarker for Active Lupus Nephritis.